Search

Your search keyword '"Lebranchu, Y."' showing total 8 results
Start Over Author "Lebranchu, Y." Language undetermined
8 results on '"Lebranchu, Y."'

1. Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies

Author

Glotz, D., Russ, G., Rostaing, L., Legendre, C., Tufveson, G., Chadban, S., Grinyo, J., Mamode, N., Rigotti, P., Couzi, L., Buchler, M., Sandrini, S., Dain, B., Garfield, Malcolm, Ogawa, M., Richard, T., Marks, W. H., Merville, P., Lebranchu, Y., Mjornstedt, L., Hughes, P., Torpey, N., and Kamar, N.

Subjects
Graft Rejection, Male, donors and donation, kidney transplantation/nephrology, 030230 surgery, sensitization, complement biology, clinical research/practice, donors and donation: deceased, immunosuppressant-fusion proteins and monoclonal antibodies, rejection: antibody-mediated (ABMR), 0302 clinical medicine, Isoantibodies, Risk Factors, deceased, Immunology and Allergy, Medicine, Pharmacology (medical), Kidney transplantation, biology, Graft Survival, Eculizumab, Middle Aged, Prognosis, practice, Tissue Donors, Survival Rate, Monoclonal, Female, Patient Safety, rejection, Antibody, medicine.drug, Adult, Adolescent, nephrology, kidney transplantation, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Young Adult, antibody-mediated (ABMR), Humans, In patient, Survival rate, Aged, Transplantation, business.industry, Kirurgi, medicine.disease, Kidney Transplantation, Complement Inactivating Agents, clinical research, Immunology, biology.protein, Kidney Failure, Chronic, Surgery, business, Follow-Up Studies
Abstract

The presence of preformed donor-specific antibodies in transplant recipients increases the risk of acute antibody-mediated rejection (AMR). Results of an open-label single-arm trial to evaluate the safety and efficacy of eculizumab in preventing acute AMR in recipients of deceased-donor kidney transplants with preformed donor-specific antibodies are reported. Participants received eculizumab as follows: 1200 mg immediately before reperfusion; 900 mg on posttransplant days 1, 7, 14, 21, and 28; and 1200 mg at weeks 5, 7, and 9. All patients received thymoglobulin induction therapy and standard maintenance immunosuppression including steroids. The primary end point was treatment failure rate, a composite of biopsy-proved grade II/III AMR (Banff 2007 criteria), graft loss, death, or loss to follow-up, within 9 weeks posttransplant. Eighty patients received transplants (48 women); the median age was 52 years (range 24-70 years). Observed treatment failure rate (8.8%) was significantly lower than expected for standard care (40%; P < .001). By 9 weeks, 3 of 80 patients had experienced AMR, and 4 of 80 had experienced graft loss. At 36 months, graft and patient survival rates were 83.4% and 91.5%, respectively. Eculizumab was well tolerated and no new safety concerns were identified. Eculizumab has the potential to provide prophylaxis against injury caused by acute AMR in such patients (EudraCT 2010-019631-35).

Published
2018

2. Human TNF-alpha induces major histocompatibility complex class-II molecules on porcine endothelial cells without affecting the proliferative response of human lymphocytes

Author

Vallée, I., Watier, H., Thibault, G., Lalmanach, Anne-Christine, Lacord, M., Gruel, Y., Lebranchu, Y., Salmon, Henri, Bardos, P., ProdInra, Migration, Unité de Pathologie Infectieuse et Immunologie [Nouzilly] (PII), and Institut National de la Recherche Agronomique (INRA)

Subjects
XENOGREFFE, Dose-Response Relationship, Drug, Swine, Tumor Necrosis Factor-alpha, [SDV]Life Sciences [q-bio], Histocompatibility Antigens Class II, Flow Cytometry, Lymphocyte Activation, FACTEUR NECROSANT DE TUMEUR, Recombinant Proteins, [SDV] Life Sciences [q-bio], Kinetics, SYSTEME MHC, Animals, Humans, Endothelium, Vascular, Aorta, Cells, Cultured, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

5. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells

Author

de Beaucoudrey, L, Puel, A, Filipe-Santos, O, Cobat, A, Ghandil, P, Chrabieh, M, Feinberg, J, von Bernuth, H, Samarina, A, Jannière, L, Fieschi, C, Stéphan, J L, Boileau, C, Lyonnet, S, Jondeau, G, Cormier-Daire, V, Le Merrer, M, Hoarau, C, Lebranchu, Y, Lortholary, O, Chandesris, M O, Tron, F, Gambineri, E, Bianchi, L, Rodriguez-Gallego, C, Zitnik, S E, Vasconcelos, J, Guedes, M, Vitor, A B, Marodi, L, Chapel, H, Reid, B, Roifman, C, Nadal, D, Reichenbach, J, Caragol, I, Garty, B Z, Dogu, F, Camcioglu, Y, Gülle, S, Sanal, O, Fischer, A, Abel, L, Stockinger, B, Picard, C, and Casanova, J L

Subjects
3. Good health

6. Variant forms of X-linked severe combined immunodeficiency disease: one or many genes?

Author

Jp, Disanto, Le Deist F, Caniglia M, Markiewicz S, Lebranchu Y, Griscelli C, Fischer A, and Genevieve de Saint Basile

Subjects
Male, Heterozygote, X Chromosome, Genetic Linkage, Chromosome Mapping, Genetic Variation, Infant, Pedigree, Phenotype, Child, Preschool, Dosage Compensation, Genetic, Mutation, Humans, Female, Severe Combined Immunodeficiency

7. RAISED URINARY PROSTAGLANDINS IN PATIENT WITHOUT BARTTER'S SYNDROME

Author

Dray F, Nivet H, B. Grenier, Lebranchu Y, and J.C. Rolland

Subjects
Prostaglandins F, medicine.medical_specialty, business.industry, Urinary system, medicine.medical_treatment, General Medicine, Bartter syndrome, medicine.disease, Hyperaldosteronism, Bartter's syndrome, Endocrinology, Internal medicine, medicine, Vomiting, In patient, medicine.symptom, business, Prostaglandin E
Published
1978

Catalog

Books, media, physical & digital resources
See catalog results